Strategy, led by Michael Saylor, purchased 267 bitcoin for $22.1 million, increasing its total holdings to 848,517 BTC at an average cost of $75,446 per coin. Alongside this bitcoin acquisition, the company repurchased $193.1 million of its preferred shares and expanded its digital credit securities buyback program to $3 billion. Strategy also reported having $5.3 billion in U.S. dollar assets, providing a strong financial cushion. This move highlights the company's dual focus on growing its bitcoin treasury while actively managing its capital structure through securities repurchases.
Strategy's bitcoin holdings total 848,517 BTC following a recent $22.1 million purchase, with an average cost of $75,446 per coin. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 19, 2026 19:21 WIB: out of 50 major cryptocurrencies tradable on Pluang, 23 rose and 25 fell. Notable moves include SXP (Solar) down 46.27% to Rp37, BAL (Balancer) up 11.14% to Rp16,297, and EOS (EOS.IO) up 8.13% to Rp12,649.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
